Conditions: Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Uterine Corpus Cancer
Interventions: Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Tazemetostat
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not **RECRUITING NOW**
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.